In vivo uptake and acute immune response to orally administered chitosan and PEG coated PLGA nanoparticles
- PMID: 20851137
- DOI: 10.1016/j.taap.2010.09.002
In vivo uptake and acute immune response to orally administered chitosan and PEG coated PLGA nanoparticles
Abstract
Nanoparticulate drug delivery systems offer great promise in addressing challenges of drug toxicity, poor bioavailability and non-specificity for a number of drugs. Much progress has been reported for nano drug delivery systems for intravenous administration, however very little is known about the effects of orally administered nanoparticles. Furthermore, the development of nanoparticulate systems necessitates a thorough understanding of the biological response post exposure. This study aimed to elucidate the in vivo uptake of chitosan and polyethylene glycol (PEG) coated Poly, DL, lactic-co-glycolic Acid (PLGA) nanoparticles and the immunological response within 24 h of oral and peritoneal administration. These PLGA nanoparticles were administered orally and peritoneally to female Balb/C mice, they were taken up by macrophages of the peritoneum. When these particles were fluorescently labelled, intracellular localisation was observed. The expression of pro-inflammatory cytokines IL-2, IL-6, IL-12p70 and TNF-α in plasma and peritoneal lavage was found to remain at low concentration in PLGA nanoparticles treated mice as well as ZnO nanoparticles during the 24 hour period. However, these were significantly increased in lipopolysaccharide (LPS) treated mice. Of these pro-inflammatory cytokines, IL-6 and IL-12p70 were produced at the highest concentration in the positive control group. The anti-inflammatory cytokines IL-10 and chemokines INF-γ, IL-4, IL-5 remained at normal levels in PLGA treated mice. IL-10 and INF-γ were significantly increased in LPS treated mice. MCP-1 was found to be significantly produced in all groups in the first hours, except the saline treated mice. These results provide the first report to detail the induction of cytokine production by PLGA nanoparticles engineered for oral applications.
Copyright © 2010 Elsevier Inc. All rights reserved.
Similar articles
-
Nasal vaccination with N-trimethyl chitosan and PLGA based nanoparticles: nanoparticle characteristics determine quality and strength of the antibody response in mice against the encapsulated antigen.Vaccine. 2010 Aug 31;28(38):6282-91. doi: 10.1016/j.vaccine.2010.06.121. Epub 2010 Jul 16. Vaccine. 2010. PMID: 20638455
-
Diphtheria toxoid loaded poly-(epsilon-caprolactone) nanoparticles as mucosal vaccine delivery systems.Methods. 2006 Feb;38(2):96-105. doi: 10.1016/j.ymeth.2005.11.003. Methods. 2006. PMID: 16442811
-
Development and characterization of hyaluronic acid-anchored PLGA nanoparticulate carriers of doxorubicin.Nanomedicine. 2007 Dec;3(4):246-57. doi: 10.1016/j.nano.2007.09.004. Nanomedicine. 2007. PMID: 18068091
-
Biodegradable microspheres targeting mucosal immune-regulating cells: new approach for treatment of inflammatory bowel disease.J Gastroenterol. 2003 Mar;38 Suppl 15:59-62. J Gastroenterol. 2003. PMID: 12698874 Review.
-
Drug Delivery Nanoparticles: Toxicity Comparison in Retinal Pigment Epithelium and Retinal Vascular Endothelial Cells.Semin Ophthalmol. 2016;31(1-2):1-9. doi: 10.3109/08820538.2015.1114865. Semin Ophthalmol. 2016. PMID: 26959123 Free PMC article. Review.
Cited by
-
Therapies and Vaccines Based on Nanoparticles for the Treatment of Systemic Fungal Infections.Front Cell Infect Microbiol. 2020 Sep 3;10:463. doi: 10.3389/fcimb.2020.00463. eCollection 2020. Front Cell Infect Microbiol. 2020. PMID: 33014889 Free PMC article. Review.
-
In Vitro and in Vivo Analyses of the Effects of Source, Length, and Charge on the Cytotoxicity and Immunocompatibility of Cellulose Nanocrystals.ACS Biomater Sci Eng. 2021 Apr 12;7(4):1450-1461. doi: 10.1021/acsbiomaterials.0c01618. Epub 2021 Mar 9. ACS Biomater Sci Eng. 2021. PMID: 33689287 Free PMC article.
-
Preparation, characterization, and optimization of primaquine-loaded solid lipid nanoparticles.Int J Nanomedicine. 2014 Aug 11;9:3865-74. doi: 10.2147/IJN.S62630. eCollection 2014. Int J Nanomedicine. 2014. PMID: 25143734 Free PMC article.
-
Methodological needs in the quality and safety characterisation of nanotechnology-based health products: Priorities for method development and standardisation.J Control Release. 2021 Aug 10;336:192-206. doi: 10.1016/j.jconrel.2021.06.016. Epub 2021 Jun 12. J Control Release. 2021. PMID: 34126169 Free PMC article. Review.
-
Polymeric Nanoparticle-Based Vaccine Adjuvants and Delivery Vehicles.Curr Top Microbiol Immunol. 2021;433:29-76. doi: 10.1007/82_2020_226. Curr Top Microbiol Immunol. 2021. PMID: 33165869 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous